medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 5

Next >>

Rev Mex Urol 2022; 82 (5)

Urologic research in the COVID-19 Era: Challenges and Opportunities

Autrán-Gómez AM, Tobia IP, Sánchez-Salas R, Paesano N, Martínez-Salamanca JI, García-Perdomo HA, Torrico RM, Rodríguez A

Language: Spanish
References: 16
Page:
PDF size: 109.78 Kb.


ABSTRACT

The Coronavirus (COVID-19) pandemic, typified as such in March 2020 by the World Health Organization (WHO), has exceeded the capacity of health systems to aid victims, and triggered a radical change in medical research, and in the monitoring of the enrollment for clinical trials in urologic fields around the world.
Last year, almost 90% of clinical sites closed patient enrollment, while at the same time, researchers around the world initiated almost 1000 COVID-19 clinical trials. This catastrophic pandemic has allowed us to expand our medical knowledge exponentially. The global urological community has created and published an infinity of scientific articles: establishing guideline reactions for diagnosis, treatment, and follow-up of the different urologic conditions across all areas of the field, reporting the experiences at urology services, and putting forward new strategies.
The Confederación Americana de Urología (CAU) has promoted international collaborative projects that have led to gaining insight into how the Latin American Urology Services faced the pandemic, including the challenges, strengths, and the areas of opportunity for urologic care. It also allowed us to increase the number and quality of publications. Also, we have created new virtual platforms and international networks to exchange our knowledge. We have as well transformed this social, economic and health crisis brought upon us by COVID-19, into a source of opportunities for the growth and promotion of research in Latin America.
Urologic patients, require researchers to work on favoring their goals. A collaborative network, the established and coordinated protocols, the safety of patients and researchers, assertive and constant communication, and effective technology use, are the essential tools to resume institutional investigation under these critical conditions.


REFERENCES

  1. WIRB-Copernicus Group. COVID-19Resources and Services from WCG: ResourceCenter: COVID-19 and Clinical Trial Operations. 2022. Available from: https://www.wcgclinical.com/covid-19/

  2. Psotka MA, Abraham WT, Fiuzat M, FilippatosG, Lindenfeld J, Ahmad T, et al. Conductof Clinical Trials in the Era of COVID-19.Journal of the American College of Cardiology.2020;76(20):2368–78. doi: https://doi.org/10.1016/j.jacc.2020.09.544

  3. Teh J, O’Connor E, Coles-Black J, LawrentschukN. Clinical trials in urological oncology: COVID-19and the potential need for a new perspective.World J Urol. 2021;39(9):3147–9. doi: https://doi.org/10.1007/s00345-020-03416-4

  4. U.S. Department of Health and Human ServicesFood and Drug Administration. FDA Guidanceon Conduct of Clinical Trials of MedicalProducts During the COVID-19 Public HealthEmergency. Food and Drug Administration(FDA or Agency); 2021.

  5. National Institutes of Health. Guidance forNIH-funded Clinical Trials and Human SubjectsStudies Affected by COVID-19. NationalInstitutes of Health; 2020.

  6. European Medicines Agency. Guidance tosponsors on how to manage clinical trials duringthe COVID-19 pandemic. United Kingdom:European Medicines Agency.; 2022. Availablefrom: https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trialsduring-covid-19-pandemic

  7. Saini KS, Heras B de las, Castro J de,Venkitaraman R, Poelman M, Srinivasan G,et al. Effect of the COVID-19 pandemic oncancer treatment and research. The LancetHaematology. 2020;7(6):e432–5. doi: https://doi.org/10.1016/S2352-3026(20)30123-X

  8. Nabhan C, Choueiri TK, Mato AR. RethinkingClinical Trials Reform During the COVID-19Pandemic. JAMA Oncology. 2020;6(9):1327–

  9. doi: https://doi.org/10.1001/jamaoncol.2020.31429. Verna EC, Serper M, Chu J, Corey K, Fix OK,Hoyt K, et al. Clinical Research in Hepatologyin the COVID-19 Pandemic and Post-PandemicEra: Challenges and the Need for Innovation.Hepatology. 2020;72(5):1819–37. doi: https://doi.org/10.1002/hep.31491

  10. Petkova E, Antman EM, Troxel AB. PoolingData From Individual Clinical Trials in theCOVID-19 Era. JAMA. 2020;324(6):543–5. doi:https://doi.org/10.1001/jama.2020.13042

  11. ICH Harmonised Guideline. Integratedaddendum to ICH E6(R1): Guideline for goodclinical practice E6(R2). International councilfor harmonisation of technical requirements forpharmaceuticals for human use (ICH); 2016.

  12. Felix C. Clinical Research in the Time ofCOVID-19. International Journal of RadiationOncology, Biology, Physics. 2020;108(2):489–90. doi: https://doi.org/10.1016/j.ijrobp.2020.06.059

  13. Abraham WT, Fiuzat M, Psotka MA, O’ConnorCM. Heart Failure Collaboratory Statementon Clinical Trials in the Landscape of COVID-19.JACC Heart Fail. 2020;8(5):423–5. doi: https://doi.org/10.1016/j.jchf.2020.03.005

  14. Wang Z, Chen G, Liu X, Du A, Li M, WangJ. How to safely and smoothly resumetrials after the COVID-19 outbreak. J GlobHealth. 2020;10(2):020310. doi: https://doi.org/10.7189/jogh.10.020310

  15. National Academies of Sciences E. IntegratingClinical Research into Epidemic Response:The Ebola Experience. Washington, D.C: TheNational Academies Press; 2017. Doi: https://doi.org/10.17226/24739

  16. American Psychological Association.Conducting research during the COVID-19pandemic. American PsychologicalAssociation. 2022.




2020     |     www.medigraphic.com